Global Cerebral Spinal Fluid (CSF) Shunt Systems Market - 2024-2031

Overview

The global cerebral spinal fluid shunt systems market reached US$ 894.2 million in 2023 and is expected to reach US$ 1398.3 million by 2031, growing at a CAGR of 5.8% during the forecast period 2024-2031.

Cerebrospinal Fluid (CSF) shunt systems are medical devices designed to divert excess cerebrospinal fluid (CSF) from one part of the brain or spinal cord to another area of the body, typically when there is an abnormal accumulation of CSF, a condition known as hydrocephalus. These systems are primarily used to treat hydrocephalus and other conditions that cause fluid buildup in the brain, which can lead to increased intracranial pressure, potentially damaging brain tissue. CSF shunt systems play a crucial role in managing conditions related to abnormal CSF buildup, helping to maintain normal brain function and prevent long-term neurological damage.

The global demand for cerebral spinal fluid shunt systems is growing due to several factors. A key driver is the increasing prevalence of neurological disorders such as hydrocephalus, traumatic brain injuries and intracranial hypertension, particularly among both the adult and pediatric populations. For instance, according to the WHO, in 2021, more than 3 billion people worldwide were living with a neurological condition. Advances in medical technologies, including more effective shunting systems and less invasive procedures, support market growth.

For instance, according to the UCLA Health Organization, hydrocephalus occurs in two out of every 1,000 births in the United States. It is not known how many people develop it after birth. Approximately 125,000 persons are living with cerebrospinal fluid (CSF) shunt systems and 33,000 shunts are placed annually in the United States.

Market Dynamics: Drivers & Restraints

Rising prevalence of hydrocephalus

The rising prevalence of hydrocephalus is significantly driving the growth of the spinal fluid shunt systems market and is expected to drive over the forecast period. Hydrocephalus, a condition characterized by the abnormal accumulation of cerebrospinal fluid in the brain, leads to increased intracranial pressure, potentially causing brain damage if untreated.

For instance, according to Medscape, the global prevalence of hydrocephalus is estimated at approximately 85 cases per 100,000 individuals, with notable variation across age groups, 88 per 100,000 in the pediatric population and 11 per 100,000 in adults. Additionally, according to Neurology India, the incidence of hydrocephalus is 123 per 100,000 births in low- and middle-income countries (LMICs) compared to 79 per 100,000 births in high-income countries. The prevalence of both congenital hydrocephalus (present from birth) and acquired hydrocephalus (due to trauma, infections, or tumors) is increasing, contributing directly to the demand for CSF shunt systems.

Normal pressure hydrocephalus, common among the elderly, is another major factor. The aging global population, particularly in developed countries, is leading to more diagnoses of normal pressure hydrocephalus, which often requires shunt intervention. For instance, according to the Alzheimer's Association, normal pressure hydrocephalus primarily affects people in their 60s and 70s. The Hydrocephalus Association estimates that nearly 700,000 adults have normal-pressure hydrocephalus

High risk of post-implantation complications

The high risk of post-implantation complications is expected to hamper the cerebral spinal fluid shunt systems market. These complications not only affect patient outcomes but also lead to additional healthcare costs, increased treatment time and a decrease in patient and provider confidence in shunt technologies. Infections are one of the most common complications after CSF shunt implantation.

For instance, according to ScienceDirect, shunt infection rates range from about 5% to 15%, with most infections resulting from wound contamination. Almost 70% of infections are caused by skin flora staphylococcal organisms. CSF shunt infections usually occur within 2 months after implantation.

Infections can lead to serious complications such as meningitis or sepsis, requiring the shunt to be replaced and the patient to undergo intensive treatment, including antibiotics or even re-surgery. The need for repeated surgeries increases the overall healthcare costs and impacts the long-term viability of shunt systems, limiting their market acceptance.

For more details on this report - Request for Sample

Segment Analysis

The global cerebral spinal fluid shunt systems market is segmented based on product type, material, valve type, indication, age group, end-user and region.

Indication:

The ventriculoperitoneal shunts segment is expected to dominate the global cerebral spinal fluid shunt systems market share

The ventriculoperitoneal shunts segment holds a major portion of the cerebral spinal fluid shunt systems market share and is expected to continue to hold a significant portion of the market share over the forecast period due to their widespread use, effectiveness and cost-efficiency in treating hydrocephalus, particularly in pediatric patients. These shunts are preferred for their ability to effectively redirect excess cerebrospinal fluid from the brain's ventricles to the peritoneal cavity (abdomen), where the fluid can be absorbed into the bloodstream.

Thus, due to the wide advantages offered by ventriculoperitoneal shunts, many major and emerging market players are focussing on these stunts. For instance, in May 2024, CereVasc, Inc. approval from the US Food and Drug Administration (FDA) to initiate its "Pivotal Study to Evaluate the Safety and Effectiveness of the CereVasc eShunt System in the Treatment of Normal Pressure Hydrocephalus" (STRIDE trial). The STRIDE pivotal study compares the safety and efficacy of its novel eShunt System for the treatment of patients with Normal Pressure Hydrocephalus to treatment with the current standard of care, the ventriculoperitoneal (VP) shunt.

Ventriculoperitoneal shunts are considered the gold standard in treating hydrocephalus, especially in congenital cases. This widespread use in both pediatric and adult populations significantly contributes to their market dominance. Ventriculoperitoneal shunts are highly effective in the long-term management of hydrocephalus, with studies showing that they are successful in reducing symptoms and improving patient outcomes, especially when timely intervention is applied.

North America is expected to hold a significant position in the global cerebral spinal fluid shunt systems market

North America region is expected to hold the largest market share over the forecast period. North America, especially the United States has a high prevalence of hydrocephalus, a major condition treated by CSF shunt systems. According to the Hydrocephalus Association, around 1 in 500 to 1,000 live births are affected by congenital hydrocephalus in the United States, leading to a significant demand for shunt devices.

For instance, according to the UCLA Health Organization, hydrocephalus occurs in two out of every 1,000 births in the United States. It is not known how many people develop it after birth. Approximately 125,000 persons are living with cerebrospinal fluid (CSF) shunt systems and 33,000 shunts are placed annually in the United States.

North America is home to the most advanced shunt technologies. Companies in the region have pioneered the development of programmable shunts and anti-siphon devices, which offer better control over cerebrospinal fluid flow and minimize the risk of complications such as infection or over-drainage. These innovations enhance patient outcomes and make CSF shunt systems more effective, leading to greater adoption and market share.

For instance, in August 2024, Aesculap, Inc. (Aesculap), in partnership with Christoph Miethke GmbH & Co. KG (MIETHKE), cleared that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for the M.scio System. This unique, non-invasive, telemetric pressure measurement system is designed to provide continuous access to long-term, intracranial pressure (ICP) monitoring of cerebrospinal fluid (CSF) for the management of hydrocephalus via a permanent, fully implantable sensor.

Asia Pacific is growing at the fastest pace in the cerebral spinal fluid shunt systems market

The Asia Pacific region is experiencing the fastest growth in the cerebral spinal fluid shunt systems market. The prevalence of hydrocephalus and other neurological disorders is rising in the Asia Pacific region. The incidence of congenital hydrocephalus in countries like India and China is on the rise, partly due to better survival rates among preterm infants and improvements in neonatal care. For example, India has seen an increase in congenital hydrocephalus diagnoses, with studies indicating a prevalence of about 0.6-1.2 per 1,000 live births.

Medical tourism is also contributing to the growth of the CSF shunt market in Asia Pacific. Countries like India, Thailand and Singapore are popular destinations for medical tourists seeking affordable and high-quality hydrocephalus treatment. For instance, according to the Ministry of Tourism, India has been ranked 10th in the Medical Tourism Index (MTI) for 2020-21 out of 46 destinations in the world by the Medical Tourism Association. The increase in medical tourism is partly due to the availability of skilled healthcare professionals and modern surgical facilities at relatively lower costs compared to Western countries.

Competitive Landscape

The major global players in the cerebral spinal fluid shunt systems market include Medtronic plc, Aesculap, Inc., Sophysa, Integra LifeSciences Corporation, Christoph Miethke GmbH & Co. KG, Delta Surgical, Anuncia Inc., Spiegelberg GmbH & Co. KG, HpBio, BIcakcIlar and among others.

Why Purchase the Report?

• Pipeline & Innovations: Insights into clinical trials, product pipelines, and upcoming advancements.
• Market Positioning: Analysis of product performance and growth potential for optimized strategies.
• Real-World Evidence: Integration of patient feedback for enhanced product outcomes.
• Physician Preferences: Insights into healthcare provider behaviors and adoption strategies.
• Regulatory & Market Updates: Coverage of recent regulations, policies, and emerging technologies.
• Competitive Insights: Analysis of market share, competitor strategies, and new entrants.
• Pricing & Market Access: Review of pricing models, reimbursement trends, and access strategies.
• Market Expansion: Strategies for entering new markets and forming partnerships.
• Regional Opportunities: Identification of high-growth regions and investment prospects.
• Supply Chain Optimization: Assessment of risks and distribution strategies.
• Sustainability & Regulation: Focus on eco-friendly practices and regulatory changes.
• Post-Market Surveillance: Enhanced safety and access through post-market data.
• Value-Based Pricing: Insights into pharmacoeconomics and data-driven R&D decisions.

The global cerebral spinal fluid shunt systems market report delivers a detailed analysis with 86 key tables, more than 85 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.